NASDAQ:ABVC ABVC BioPharma (ABVC) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free ABVC Stock Alerts $1.04 +0.05 (+5.05%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.94▼$1.0450-Day Range$0.99▼$1.3752-Week Range$0.67▼$9.60Volume307,886 shsAverage Volume1.92 million shsMarket Capitalization$10.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get ABVC BioPharma alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About ABVC BioPharma Stock (NASDAQ:ABVC)ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Read More ABVC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABVC Stock News HeadlinesApril 18, 2024 | investing.comABVC BioPharma inks licensing deal for cancer drugApril 18, 2024 | finanznachrichten.deABVC BioPharma, Inc.: AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 18, 2024 | globenewswire.comAiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareApril 17, 2024 | markets.businessinsider.comABVC BioPharma Enters Licensing Agreement With OncoX For Commercialization Of BLEX 404April 17, 2024 | finance.yahoo.comABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MApril 17, 2024 | globenewswire.comABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MApril 10, 2024 | globenewswire.comABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 28, 2024 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MMarch 27, 2024 | msn.comWhy ABVC BioPharma Stock Is Up TodayMarch 26, 2024 | markets.businessinsider.comABVC Announces Global Licensing Deal With ForSeeCon Eye For VitargusMarch 26, 2024 | globenewswire.comABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MMarch 21, 2024 | finance.yahoo.comAiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million DollarsMarch 19, 2024 | ca.finance.yahoo.comABVC BioPharma, Inc. (ABVC) Interactive Stock Chart - Yahoo FinanceMarch 19, 2024 | globenewswire.comABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia MagazineMarch 14, 2024 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateMarch 14, 2024 | globenewswire.comABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateFebruary 27, 2024 | finance.yahoo.comABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion DollarsFebruary 15, 2024 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 15, 2024 | markets.businessinsider.comABVC Signes Agreement To License Its 'Know-How' To SPIFebruary 15, 2024 | finance.yahoo.comABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 15, 2024 | globenewswire.comABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 12, 2024 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)February 12, 2024 | markets.businessinsider.comABVC BioPharma Receives Australian Patent For PDC-1421 For Treatment Of MDDFebruary 12, 2024 | finance.yahoo.comABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)February 9, 2024 | msn.comABVC BioPharma Conducts Private Equity and Warrants SaleSee More Headlines Receive ABVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/23/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABVC CUSIPN/A CIK1173313 Webwww.abvcpharma.com Phone(510)-668-0881FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,520,000.00 Net Margins-6,919.08% Pretax Margin-6,989.44% Return on Equity-226.65% Return on Assets-82.26% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.28 Sales & Book Value Annual Sales$150,000.00 Price / Sales73.22 Cash FlowN/A Price / Cash FlowN/A Book Value$1.02 per share Price / Book1.02Miscellaneous Outstanding Shares10,560,000Free Float9,303,000Market Cap$10.98 million OptionableNot Optionable Beta0.75 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Eugene Jiang (Age 38)Chairman & Chief Business Officer Comp: $200kDr. Uttam Yashwant Patil Ph.D. (Age 38)Chief Executive Officer Mr. Leeds Chow (Age 34)CFO & Principal Accounting Officer Comp: $180kDr. Tsung-Shann Jiang EMBA (Age 70)Ph.D., Chief Scientific Officer, Chief Strategy Officer & Director Comp: $200kKey CompetitorsGalera TherapeuticsNASDAQ:GRTXImunonNASDAQ:IMNNPurple BiotechNASDAQ:PPBTMonopar TherapeuticsNASDAQ:MNPRRedHill BiopharmaNASDAQ:RDHLView All Competitors ABVC Stock Analysis - Frequently Asked Questions How have ABVC shares performed in 2024? ABVC BioPharma's stock was trading at $1.16 at the start of the year. Since then, ABVC shares have decreased by 10.3% and is now trading at $1.04. View the best growth stocks for 2024 here. Are investors shorting ABVC BioPharma? ABVC BioPharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,320,000 shares, an increase of 1,146.5% from the March 15th total of 105,900 shares. Based on an average trading volume of 706,600 shares, the short-interest ratio is presently 1.9 days. Approximately 15.2% of the shares of the stock are sold short. View ABVC BioPharma's Short Interest. When is ABVC BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ABVC earnings forecast. How were ABVC BioPharma's earnings last quarter? ABVC BioPharma, Inc. (NASDAQ:ABVC) announced its earnings results on Wednesday, March, 13th. The company reported ($0.35) earnings per share for the quarter. ABVC BioPharma had a negative net margin of 6,919.08% and a negative trailing twelve-month return on equity of 226.65%. When did ABVC BioPharma's stock split? ABVC BioPharma shares reverse split on Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did ABVC BioPharma IPO? ABVC BioPharma (ABVC) raised $7 million in an IPO on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share. How do I buy shares of ABVC BioPharma? Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABVC) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
